Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study

Asian J Surg. 2023 Dec;46(12):5482-5483. doi: 10.1016/j.asjsur.2023.07.123. Epub 2023 Aug 2.

Authors

Li-Na Liu¹, Yu-Shan Cui¹, Bai-Jun Fang²

Affiliations

¹ Department of Hematology, Henan Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan, PR China.
² Department of Hematology, Henan Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan, PR China. Electronic address: zlyyfangbaijun1051@zzu.edu.cn.

PMID: 37541902
DOI: 10.1016/j.asjsur.2023.07.123

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / adverse effects
Dexamethasone
Disease-Free Survival
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local
Purpura, Thrombocytopenic, Idiopathic* / drug therapy

Substances

Bortezomib
Dexamethasone